Health Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Agendia B.V.

Agendia's Breast Cancer Test MammaPrint Standard of Care at Netherlands Cancer Institute - AVL

announced that its signature breast cancer test MammaPrint(R) will be offered as standard of care for all eligible early stage breast cancer patients at the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL).

The NKI-AVL believes MammaPrint provides better guidance for decisions regarding adjuvant therapy. As one of the participating centers in the MINDACT trial NKI-AVL is already offering MammaPrint to patients and will continue to do so. In future, however, NKI-AVL will also make MammaPrint available to patients who fall outside MINDACT's inclusion criteria.

...

• View Other Issues of Health Business Week
  
• View Other NewsRx Publications